相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma
Siong-Seng Liau et al.
CLINICAL CANCER RESEARCH (2008)
Gemcitabine resistance in pancreatic cancer: Picking the key players
Michael P. Kim et al.
CLINICAL CANCER RESEARCH (2008)
Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells
Justin Hering et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Human ENT1 is predictive of response in patients with pancreatic cancer treated with gemcitabine: Results from the RTOG 9704 prospective randomized trial
J. Farrell et al.
PANCREAS (2007)
Clinical phase I and pharmacology study of gemcitabine (2′,2′-difluorodeoxycytidine) administered in a two-weekly schedule
G. J. Peters et al.
JOURNAL OF CHEMOTHERAPY (2007)
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
Y. Nakano et al.
BRITISH JOURNAL OF CANCER (2007)
Predictive factors in pancreatic ductal adenocarcinoma: Role of the inflammatory response
Bobby Tingstedt et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2007)
Molecular mechanisms of pancreatic cancer and potential targets of treatment
Ursula Aho et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2007)
The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs
Jing Zhang et al.
CANCER AND METASTASIS REVIEWS (2007)
HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma
Siong-Seng Liau et al.
CANCER RESEARCH (2006)
Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model
Masanori Tsujie et al.
PANCREAS (2006)
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine
E Giovannetti et al.
CANCER RESEARCH (2006)
Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer
Elisa Giovannetti et al.
MOLECULAR CANCER THERAPEUTICS (2006)
In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate
P Chen et al.
ANTI-CANCER DRUGS (2006)
In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant
AM Bergman et al.
CANCER RESEARCH (2005)
Impact of gemcitabine on the treatment of metastatic pancreatic cancer
H Ishii et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2005)
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
JP Neoptolemos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma
J Spratlin et al.
CLINICAL CANCER RESEARCH (2004)
Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts
AM Bergman et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2004)
Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death
A Arlt et al.
ONCOGENE (2003)
The cost of treating pancreatic cancer -: A cohort study based on patients' records from four hospitals in Sweden
J Hjelmgren et al.
ACTA ONCOLOGICA (2003)
Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)
AM Bergman et al.
DRUG RESISTANCE UPDATES (2002)
分享论文
